Business Context and Reporting Period
This Form 8-K Current Report was filed by CalciMedica, Inc. on June 12, 2023. The report primarily addresses a corporate governance and market listing event rather than periodic financial performance.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the approval of the company's stock listing.
Material Changes
- Nasdaq Listing Approval: The Nasdaq Stock Market LLC approved CalciMedica's application to list its common stock on the Nasdaq Capital Market under the ticker symbol "CALC."
- Trading Commencement: The company expects trading on the Nasdaq Capital Market to begin at the market open on June 14, 2023.
- Previous Trading Venue: Prior to this approval, the company's common stock began trading on the OTCQB on April 26, 2023.
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding the Nasdaq listing. Management notes that actual outcomes may differ due to uncertainties, including:
- The ability to maintain compliance with Nasdaq continued listing standards.
- The impact of fluctuations in global financial markets on the business.
Investors are directed to the "Risk Factors" section of the company's most recent Form 10-Q (filed May 12, 2023) and Form 10-K for a comprehensive list of risks.
Investor Verification Checklist
- Verify the commencement of trading on the Nasdaq Capital Market on June 14, 2023.
- Review the press release (Exhibit 99.1) for additional details on the listing.
- Consult the most recent Form 10-Q and Form 10-K for financial health and risk factors, as this 8-K contains no financial data.
- Monitor future filings for confirmation of continued compliance with Nasdaq listing standards.